PedAM
Pediatric Disease Annotations & Medicines
| Disease | severe combined immunodeficiency |
| Phenotype | C0026764|myeloma |
| Sentences | 5 |
| PubMedID- 22425892 | As shown in figure 2a, 2b and supplementary figure 1, severe bone resorption was observed in 20 of 24 scid-hu mice injected with primary myeloma cells with high/detectable p38 activity from eight patients, while none of 12 mice injected with primary myeloma cells with undetectable pp38 (from four patients) had visible bone resorption, as detected by radiography at 8 weeks after tumor inoculation. |
| PubMedID- 21693026 | We then determined whether the reduced tumor size in the scid-rab mice inoculated with myeloma cells stably expressing pf4 or p17-70 was associated with a reduction in the production of the human immunoglobulin light chain. |
| PubMedID- 21188144 | scid-hu mice engrafted with hg myeloma cells were treated with saline or pth for 4 weeks. |
| PubMedID- 24990525 | More recently, experiments utilizing scid mice injected with human myeloma cells demonstrated that the ccr1 antagonist bx471 reduced osteolytic lesions, while the ccr1 antagonist mln-3897 prevented myeloma cell adhesion to osteoclasts. |
| PubMedID- 23226303 | However, in another study, bortezomib had no effect on femur bmd in a myeloma model of 15-week-old cb.17/icr-scid mice [45], which is in line with our data. |
Page: 1